Wearable glucose sensor compared with the standard sugar test for gestational diabetes
Tests a continuous glucose sensor for finding gestational diabetes in pregnant women.
Key facts
- Who runs it
- KK Women's and Children's Hospital
- Where
- Singapore1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Continuous Glucose Monitoring Glycemic cHAracterization During Pregnancy
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Jul 2024
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Continuous glucose monitoring
- Record updated
- 10 August 2026
Who can take part
The trial is looking for pregnant women of Chinese or Indian ethnicity who have a glucose tolerance test (OGTT) planned. They will wear a glucose sensor on the upper arm for up to 10 days.
- Age
- 21 to 45 years
- Sex
- Women only (pregnant)
- Disease stage
- Pregnant, with the OGTT planned between 20-35 weeks of pregnancy at KK Women's and Children's Hospital.
- Main reasons for not taking part
- Serious skin conditions (for example eczema) that stop you wearing the sensor for 10 days
- Type 1 or Type 2 diabetes that started before the pregnancy
- Mental illness that makes it impossible to give informed consent
- Pregnancy diabetes (GDM) found early, in the 1st or early 2nd trimester
This trial only enrols pregnant participants. The registry sentence this rests on: 1. Pregnant women of only Chinese or Indian ethnicity
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Pregnant women of only Chinese or Indian ethnicity
- Pregnant women between age 21--45 years old
- Oral glucose tolerance test (OGTT) to be scheduled between 20-35 weeks gestational age
- OGTT to be done at KK Women's and Children's Hospital
Who cannot take part
- Women with serious skin conditions (e.g. eczema) that precludes wearing the sensor for 10 days
- Exclusion criteria were pre-existing Type 1 or Type 2 diabetes, mental illness precluding informed consent and women who were diagnosed early (1st or early 2nd trimester for GDM)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Gestational diabetes or glucose metabolism disorders or metabolic disease
This trial is currently available in Singapore.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Our study named Integrated Continuous glucose monitoring glycemic cHAracterization during Pregnancy in comparison with oral glucose tolerance test (I-CHAP) aims to establish much needed preliminary evidence in our Asian population to show the capabilities of CGM use and its wealth of data for GDM diagnosis. This study aims to test the following aims and hypotheses in a single-armed intervention pilot trial study of pregnant women undergoing the oral glucose tolerance test:
Read full original descriptionShow less
Aim 1. To characterize CGM glucose values with the 3-point blood glucose measured during the OGTT procedure.
The investigators hypothesize that the CGM glucose values at single time points while fasted, and after the 75-g glucose load will be positively correlated with 3-timepoint blood glucose values captured during the OGTT.
Aim 2. To correlate the CGM glucose excursions and CGM-derived metrics (glycaemic variability and glycaemic control) with maternal-fetal outcomes and treatment outcomes.
The investigators hypothesize that higher AUC, glycemic variability and poorer glycaemic control will better distinguish maternal-fetal outcomes and treatment outcomes, compared to the OGTT.
Aim 3. To describe the acceptability of using the Dexcom G6 CGM as a diagnostic tool instead of the OGTT. The investigators hypothesize that a higher proportion of participants will report CGM to be more acceptable than the OGTT for GDM diagnosis.
The group in the trial
- Continuous glucose monitoring armTreatment being tested
Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
Treatment: Continuous glucose monitoring
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Integrated Continuous Glucose Monitoring Glycemic cHAracterization During Pregnancy in Comparison With OGTT (I-CHAP)
- Plain-language title
- Wearable glucose sensor compared with the standard sugar test for gestational diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06357728, who can take part
- Record updated
- 10 August 2026